Apollon Wealth Management LLC Purchases New Position in Liquidia Corporation $LQDA

Apollon Wealth Management LLC purchased a new position in Liquidia Corporation (NASDAQ:LQDA) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,535 shares of the company’s stock, valued at approximately $247,000.

A number of other hedge funds also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia in the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia during the 2nd quarter valued at approximately $25,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the 3rd quarter valued at approximately $34,000. Covestor Ltd grew its stake in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after acquiring an additional 4,927 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 139,390 shares of Liquidia stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total value of $5,595,114.60. Following the sale, the chief financial officer owned 353,356 shares in the company, valued at $14,183,709.84. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 318,893 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director directly owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,327,030 shares of company stock worth $134,983,644. Insiders own 25.60% of the company’s stock.

Liquidia Price Performance

Liquidia stock opened at $81.23 on Wednesday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The company has a 50-day moving average price of $62.48 and a 200 day moving average price of $46.03. Liquidia Corporation has a 12-month low of $12.21 and a 12-month high of $82.00. The stock has a market cap of $7.22 billion, a P/E ratio of 580.26 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s revenue for the quarter was up 4187.1% on a year-over-year basis. Sell-side analysts anticipate that Liquidia Corporation will post 3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on LQDA shares. Bank of America restated a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Needham & Company LLC boosted their target price on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. BTIG Research upped their price target on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Finally, Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average price target of $68.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).